Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMYTCVE:BMKNASDAQ:FIRETSE:HLSCVE:ICC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsBMKMacDonald Mines ExplorationC$0.04-12.5%C$0.05C$0.03▼C$0.09C$1.33M0.475,091 shs2,000 shsFIRE(FIRE)$0.00$0.00▼$0.00N/AN/AN/AN/AHLSHLS TherapeuticsC$4.73-0.4%C$4.29C$3.34▼C$7.12C$150.98M1.169,501 shs4,512 shsICCICC LabsC$1.62-5.8%C$1.62C$0.87▼C$2.00C$223.64MN/A799,310 shs646,156 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%BMKMacDonald Mines Exploration0.00%-12.50%-22.22%-22.22%-41.67%FIRE(FIRE)0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics-0.42%-3.86%+31.02%+15.65%-18.17%ICCICC Labs0.00%0.00%0.00%0.00%0.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AN/AN/AN/AHLSHLS Therapeutics0.0655 of 5 stars1.10.01.70.00.60.80.0ICCICC LabsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt PharmaN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AHLSHLS Therapeutics2.25HoldC$4.58-3.28% DownsideICCICC LabsN/AN/AN/AN/ACurrent Analyst RatingsLatest BMK, AMYT, ICC, HLS, and FIRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024HLSHLS TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$6.50 ➝ C$5.003/15/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$4.35 ➝ C$4.152/22/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$5.00 ➝ C$4.352/6/2024HLSHLS TherapeuticsClarus SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63BMKMacDonald Mines ExplorationC$-74K-17.92C$0.00 per share13.00C($0.01) per share-3.50FIRE(FIRE)N/AN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$63.07M2.39C$0.31 per share15.22C$3.06 per share1.55ICCICC LabsC$533.68K419.04C$0.06 per share28.42C$0.29 per share5.68Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/ABMKMacDonald Mines Exploration-C$1.28M-C$0.02N/A∞N/AN/A-1,679.48%-324.12%6/4/2024 (Estimated)FIRE(FIRE)N/AN/A0.00N/AN/AN/AN/AN/AN/AHLSHLS Therapeutics-C$27.53M-C$1.16N/A∞N/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)ICCICC LabsN/AC$0.0295.29∞N/AN/AN/AN/AN/ALatest BMK, AMYT, ICC, HLS, and FIRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023HLSHLS Therapeutics-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.23%N/AN/A N/AICCICC LabsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94BMKMacDonald Mines Exploration3.840.220.27FIRE(FIRE)N/AN/AN/AHLSHLS Therapeutics89.691.651.01ICCICC LabsN/A24.848.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%BMKMacDonald Mines Exploration1.10%FIRE(FIRE)N/AHLSHLS Therapeutics59.62%ICCICC LabsN/AInsider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%BMKMacDonald Mines Exploration7.58%FIRE(FIRE)N/AHLSHLS Therapeutics0.49%ICCICC LabsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableBMKMacDonald Mines Exploration237.88 millionN/ANot OptionableFIRE(FIRE)N/AN/AN/ANot OptionableHLSHLS Therapeutics9131.92 millionN/ANot OptionableICCICC LabsN/A138.05 millionN/ANot OptionableBMK, AMYT, ICC, HLS, and FIRE HeadlinesSourceHeadlineBurkina Faso: Army Massacres 223 Villagershrw.org - April 26 at 4:30 AMToffee to stream ICC T20 World Cup in Bangladeshthedailystar.net - April 25 at 6:29 PMVirat Kohli Controversial Dismissal In RCB Vs KKR Explained: What Does ICC Rules Say About Popping Creasemsn.com - April 23 at 12:02 AMThank You, Goodnight: The Bon Jovi Story: What's The Legendary Band's Docuseries About And How To Stream Online? All You Need To Knowmsn.com - April 22 at 7:02 PMSourav Ganguly Roots for THIS Indian Player to Open Alongside Rohit Sharma in ICC T20I World Cuppinkvilla.com - April 22 at 7:02 PM10 held for attempting to murder mason over parking rowtimesofindia.indiatimes.com - April 21 at 7:39 PMDarfur villages torched in echo of earlier genocide, report saystheglobeandmail.com - April 19 at 8:48 PMJust not cricket: Indian politicians bat for powermsn.com - April 19 at 8:48 PMRussia-Ukraine war: Zelenskiy says west must do more after 14 killed in Russian strike on Chernihiv – as it happenedtheguardian.com - April 19 at 8:48 PMPakistan-West Indies ODI series starts todaybrecorder.com - April 17 at 8:14 PMRussia-Ukraine war live: Zelenskiy says west must do more after 14 killed in Russian strike on Chernihivmsn.com - April 17 at 3:14 PMLoving Living Local: ICC Performing Artscentralillinoisproud.com - April 17 at 10:13 AMMushtaq Ahmed joins Bangladesh as spin bowling coach for T20 World Cupbrecorder.com - April 16 at 2:03 PMICC Men’s Test Player Rankingsthedailystar.net - April 12 at 12:27 AMInterstate Connecting Components (ICC) Features OTTO Controls’ P6 Series Sealed Limit Switches for Military and Aerospace Applicationsfinance.yahoo.com - April 8 at 10:15 AMSri Lankan appointed CWI men’s academy head coachguardian.co.tt - April 7 at 2:01 PMAmid turbulent times, ICC elects 1st Japanese presidentasahi.com - April 6 at 7:48 PMInterview: Unny Radhakrishnan, CEO, Digitas Indiafinancialexpress.com - April 5 at 12:18 AMDr Michael Mosley busts the seven biggest sleep mythsmsn.com - April 5 at 12:18 AMIhsanullah's injury treatment puts PCB's medical department under scanner yet againmsn.com - April 5 at 12:18 AMOutrage Erupts Over Claimed Watering Down of 2024 Model Energy Codeenr.com - April 4 at 2:17 PMICC story: States rush to combat AI threat to electionsindianacitizen.org - March 29 at 12:39 PMToyota developing color-changing paintcentralillinoisproud.com - March 29 at 7:36 AMEPA bans most common form of cancer-causing asbestos - that has continued to be used in insulation, home appliances and brake pads despite links to 40,000 deaths a yeardailymail.co.uk - March 18 at 4:21 PMNew MarketBeat Followers Over TimeCompany DescriptionsAmryt PharmaNASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.MacDonald Mines ExplorationCVE:BMKMacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.(FIRE)NASDAQ:FIRESourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.HLS TherapeuticsTSE:HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.ICC LabsCVE:ICCICC Labs Inc., through its subsidiaries, produces and sells cannabis in Uruguay. It offers recreational cannabis, medicinal cannabis, cannabinoid extracts, and by-products for medicinal, recreational, and industrial use, as well as industrial hemp. The company is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.